Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary - About
Telix Pharmaceuticals Limited (TLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: TLX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -6.81% | Avg. Invested days 15 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.23B USD | Price to earnings Ratio 173.44 | 1Y Target Price 20.19 |
Price to earnings Ratio 173.44 | 1Y Target Price 20.19 | ||
Volume (30-day avg) 16601 | Beta 2.38 | 52 Weeks Range 14.01 - 20.00 | Updated Date 02/21/2025 |
52 Weeks Range 14.01 - 20.00 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.09 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.62% | Operating Margin (TTM) 9.49% |
Management Effectiveness
Return on Assets (TTM) 7.97% | Return on Equity (TTM) 20.49% |
Valuation
Trailing PE 173.44 | Forward PE 77.52 | Enterprise Value 5203158084 | Price to Sales(TTM) 8.09 |
Enterprise Value 5203158084 | Price to Sales(TTM) 8.09 | ||
Enterprise Value to Revenue 12.96 | Enterprise Value to EBITDA 113.13 | Shares Outstanding 334724000 | Shares Floating 282348658 |
Shares Outstanding 334724000 | Shares Floating 282348658 | ||
Percent Insiders - | Percent Institutions - |
About Telix Pharmaceuticals Limited
Exchange NASDAQ | Headquaters North Melbourne, VIC, Australia | ||
IPO Launch date 2024-11-14 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://telixpharma.com |
Full time employees - | Website https://telixpharma.com | ||
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.